ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 27 of 68
Up
УЖМБС 2021, 6(5): 193–198
https://doi.org/10.26693/jmbs06.05.193
Clinical Medicine

Functional State of Liver in Patients with Progressing Chronic Myeloid Leukemia

Maikut-Zabrodskaya I. M.
Abstract

Chronic myeloid leukemia is found in approximately 20% of newly diagnosed cases of leukemia in adults. In Europe and North America, chronic myeloid leukemia ranks third among leukemias (after acute leukemias and chronic lymphoblastic leukemia). The problem of diagnosis, treatment, rehabilitation and adaptation of patients with chronic myeloid leukemia is relevant, as there is a gradual increase in the incidence of this disease both in the world and in our country. Some progress has been achieved in the treatment of patients with oncohematological diseases, in particular chronic myeloid leukemia. Chronic myeloid leukemia is a clonal myeloproliferative disease in which as a result of specific translocation of chromosomal sites between 9 and 22 chromosomes, a khimeric BCR-ABL gene with tyrosine kinase activity is formed. The purpose of the study was to investigate the main biochemical parameters that characterize protein and pigment metabolism, the activity of key enzymes in patients with chronic myeloblastic leukemia at different stages of the disease for further prospects of optimizing diagnosis, predicting the course of the disease in clinical practice. Materials and methods. The functional state of liver in 77 patients at different stages of chronic myeloid leukemia was studied. All patients admitted to the hospital were examined with the use of clinical, laboratory, instrumental and special research methods, and were consulted by specialists of related specialties, if necessary. The main biochemical parameters that characterize protein and pigment metabolism, the activity of key enzymes in patients with chronic myeloid leukemia of peripheral venous blood was determined by the method of V. Menshikov (1987). Results and discussion. The content of biochemical parameters that characterize protein and pigment metabolism, the activity of key enzymes in patients with chronic myeloid leukemia has been studied. It was found that biochemical parameters that characterize protein and pigment metabolism, the activity of key enzymes in patients with chronic myeloid leukemia is associated with an increase in the studied indicator (p<0,05). The article discusses the possible causes and pathogenetic mechanisms of the identified changes. As the disease progressed the changes of protein, pigment and enzyme kinds of metabolism were revealed. The article discusses possible pathophysiological mechanisms of the identified changes. Conclusion. In patients with chronic myeloid leukemia, there is an imbalance in protein, pigment metabolism, and the activity of some liver enzymes. With the progression of chronic myeloid leukemia, the functional state of the liver deteriorates

Keywords: chronic myeloid leukemia, liver, functional state, metabolism

Full text: PDF (Ukr) 263K

References
  1. Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015 Apr; 94 Suppl 2: S241-247. https://www.ncbi.nlm.nih.gov/pubmed/25814090. https://doi.org/10.1007/s00277-015-2314-2
  2. Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015 Jun; 29(6): 1336-1343. https://www.ncbi.nlm.nih.gov/pubmed/25783795. https://doi.org/10.1038/leu.2015.73
  3. Smith AG, Painter D, Howell DA, Evans P, Smith G, Patmore R, et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open. 2014 Jan 15; 4(1): e004266. https://www.ncbi.nlm.nih.gov/pubmed/24435897. https://www.ncbi.nlm.nih.gov/pmc/articles/3902525. https://doi.org/10.1136/bmjopen-2013-004266
  4. Bajdurin SA. Klinicheskaja gematologija: rukovodstvo dlja vrachej [Clinical haematology: guide for physicans]. Каraganda: «АКНYР»; 2018. 400 p. [Russian]
  5. Bajdurin SA, Kabibulatova AE, Nakysh AT. K voprosu o vyzhyvaemosti pacientov s CML na fone terapii ingibitorami tirozinkinasy [To a question of the survival of patients with CML using tyrosine kinase inhibitors in their therapy]. Hematologija. Transfusiologija. Vostochnaja Evropa. 2017; 3(2): 147-148. [Russian]
  6. Greer JP, Arber DA, Glader B, Eds. Wintrobe’s clinical hematology. Philadelphia: Lippincott Williams & Wilkins; 2014. 2278 p.
  7. Volkova MA. Сlinical oncohematology. A manual for the physician. Ed by MA Volkova. 2nd ed, updated. M: Medytsyna Publichers; 2007. 1120 p.
  8. Luniova GG, Ed. Klinichna biochimiia [Clinical Biochemistry]. Handbook. K: Atika; 2013. 1156 p. [Ukrainian]
  9. Rukavitsin OA, Ed. Gematologija: nazional’noe rukovodstvo [Hematology: national guide]. M: Izdatelskaja gruppa “GEOTAR-Media”; 2015. 776 p. [Russian]
  10. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 8; 122(6): 872-884. https://www.ncbi.nlm.nih.gov/pubmed/23803709. https://www.ncbi.nlm.nih.gov/pmc/articles/4915804. https://doi.org/10.1182/blood-2013-05-501569
  11. Menshikov V, Ed. Laboratornye metody issledovaniya v klinicheskoj practike [Laboratory Methods in Clinical Practice: Handbook]. M: Medytsyna; 1987: 174-197, 205, 212, 225-228, 230. [Russian]